Skip to Main Content
Beta test
our new site.
(
NLM Technical Bulletin
)
Home
Search
Study Topics
Glossary
Full Text View
Tabular View
No Study Results Posted
Related Studies
Evaluating Safety and Efficacy of TOL101 Induction Versus Anti-Thymocyte Globulin to Prevent Kidney Transplant Rejection
This study is currently recruiting participants.
Verified September 2011
by Tolera Therapeutics, Inc
Study NCT01154387 Information provided by Tolera Therapeutics, Inc
First Received on June 26, 2010. Last Updated on September 21, 2011
History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
End Stage Renal Disease
Renal Transplant
Additional conditions recognized in this trial
Kidney Diseases
Kidney Failure, Chronic
More general conditions related to this trial
Renal Insufficiency
Renal Insufficiency, Chronic
Urologic Diseases
Interventions listed in this trial
Anti-Thymocyte Globulin
TOL101
Steroids
Tacrolimus
Mycophenolate mofetil (MMF)
Additional drug interventions recognized in this trial
Antilymphocyte Serum
Mycophenolate mofetil
Mycophenolic Acid
More general drug interventions related to this trial
Antibiotics, Antineoplastic
Antineoplastic Agents
Enzyme Inhibitors
Immunologic Factors
Immunosuppressive Agents
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Physiological Effects of Drugs
Therapeutic Uses
Sponsors listed in this trial
Tolera Therapeutics, Inc
Back to top of Main Content
